Search Results - "Bumes, E"

Reduced expression of CYLD in human colon and hepatocellular carcinomas by Hellerbrand, Claus, Bumes, Elisabeth, Bataille, Frauke, Dietmaier, Wolfgang, Massoumi, Ramin, Bosserhoff, Anja K.

“…CYLD was originally identified as a tumor suppressor that is mutated in familial cylindromatosis. Recent studies suggested a role for CYLD in nuclear…”
Get full text

Severe tick-borne encephalomyelitis with lack of cerebrospinal fluid pleocytosis by Pöschl, P, Kleiter, I, Grubwinkler, S, Bumes, E, Bogdahn, U, Dobler, G, Steinbrecher, A

“…Tick borne encephalitis (TBE) is an important viral encephalitis in central and eastern Europe. Cerebrospinal fluid (CSF) pleocytosis has been described in all…”
Get more information

P11.06.A NEUROPLASTIC CHANGES IN VISUAL NETWORK CONNECTIVITY AND VISUAL COGNITIVE FUNCTIONING IN BRAIN TUMOR PATIENTS WITH LESIONS IN THE OPTIC RADIATION by Rosengarth, K, Hense, K, Deuter, D, Bumes, E, Lenglinger, M, Doenitz, C, Hau, P, Schmidt, N

“…Abstract BACKGROUND The influence of brain tumors along important structures of the visual pathway on the overall organization of the visual system and visual…”
Get full text

P20.11.A DIAGNOSTIC DELAY OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) MAY BE CAUSED BY INFLAMMATORY DIFFERENTIAL DIAGNOSES by Beyer, I, Proescholdt, M, Wiesinger, I, Bumes, E, Haedenkamp, T, Fischl, A, Lee, D, Koelbl, O, Schmidt, N O, Wendl, C, Pukrop, T, Mayer, S, Riemenschneider, M J, Linker, R, Hau, P

“…Abstract BACKGROUND PCNSL is a rare extranodal subtype of B-cell non-Hodgkin lymphoma initially located in the central nervous system. It can only be finally…”
Get full text

OS08.4.A Retrospective analysis of in vivo 1H-magnetic resonance spectroscopy based on a machine learning approach enables reliable prediction of IDH mutation in patients with glioma by Bumes, E, Fellner, C, Lenz, S, Linker, R, Weis, S, Wendl, C, Wimmer, S, Hau, P, Gronwald, W, Hutterer, M

“…Abstract BACKGROUND Mutation of isocitrate dehydrogenase (IDH) is not only an important landmark in the development of low-grade gliomas, but also has…”
Get full text

P08.04.B DOES PSYCHO-ONCOLOGICAL CARE AFFECT HEALTH-RELATED QUALITY OF LIFE AND PATIENT AND CAREGIVER SATISFACTION IN IDH WILD-TYPE GLIOMA? - A PROSPECTIVE STUDY by Fischl, A, Gerken, M, Haedenkamp, T, Hillberg, A, Klinkhammer-Schalke, M, Koelbl, O, Lindberg-Scharf, P, Linker, R, Proescholdt, M, Pukrop, T, Riemenschneider, M J, Roos, P, Schmidt, N, Hau, P, Bumes, E

“…Abstract BACKGROUND Isocitrate dehydrogenase wild-type (IDHwt) gliomas are uncurable primary tumors of the brain and impose a high burden on affected patients…”
Get full text

P11.65.B TEMPORAL MUSCLE THICKNESS AS A PROGNOSTIC MARKER IN A REAL-LIFE COHORT OF NEWLY DIAGNOSED MGMT PROMOTER METHYLATED GLIOBLASTOMA PATIENTS: A MULTICENTRIC IMAGING ANALYSIS by Lazaridis, L, Moenninghoff, C, Schmidt, T, Agkatsev, S, Blau, T, Spille, D, Heider, S, Schulz, T, Bumes, E, Oster, C, Stummer, W, Kessler, A, Seidel, C, Hau, P, Sure, U, Keyvani, K, Herrlinger, U, Grauer, O, Kleinschnitz, C, Stuschke, M, Herrmann, K, Deuschl, C, Scheffler, B, Kebir, S, Glas, M

“…Abstract BACKGROUND In cranial magnetic resonance imaging (MRI) assessed temporal muscle thickness (TMT) correlates with lumbar skeletal muscle mass, which…”
Get full text

P11.65.B TEMPORAL MUSCLE THICKNESS AS A PROGNOSTIC MARKER IN A REAL-LIFE COHORT OF NEWLY DIAGNOSEDMGMT PROMOTER METHYLATED GLIOBLASTOMA PATIENTS: A MULTICENTRIC IMAGING ANALYSIS by Lazaridis, L, Moenninghoff, C, Schmidt, T, Agkatsev, S, Blau, T, Spille, D, Heider, S, Schulz, T, Bumes, E, Oster, C, Stummer, W, Kessler, A, Seidel, C, Hau, P, Sure, U, Keyvani, K, Herrlinger, U, Grauer, O, Kleinschnitz, C, Stuschke, M, Herrmann, K, Deuschl, C, Scheffler, B, Kebir, S, Glas, M

Get full text

P11.15.B First multicentric real-life experience with the combination of lomustine and temozolomide in newly diagnosedMGMT promoter methylatedIDH wildtype glioblastoma by Lazaridis, L, Schmidt, T, Agkatsev, S, Blau, T, Spille, D, Heider, S, Schulz, T, Bumes, E, Oster, C, Feldheim, J, Stummer, W, Kessler, A, Seidel, C, Hau, P, Sure, U, Keyvani, K, Herrlinger, U, Kleinschnitz, C, Stuschke, M, Herrmann, K, Deuschl, C, Hattingen, E, Scheffler, B, Kebir, S, Glas, M

Get full text

P11.15.B First multicentric real-life experience with the combination of lomustine and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma by Lazaridis, L, Schmidt, T, Agkatsev, S, Blau, T, Spille, D, Heider, S, Schulz, T, Bumes, E, Oster, C, Feldheim, J, Stummer, W, Kessler, A, Seidel, C, Hau, P, Sure, U, Keyvani, K, Herrlinger, U, Kleinschnitz, C, Stuschke, M, Herrmann, K, Deuschl, C, Hattingen, E, Scheffler, B, Kebir, S, Glas, M

“…Abstract Background The CeTeG/NOA-09 trial assessed in a randomized phase 3 setting, whether combined treatment of lomustine together with temozolomide was…”
Get full text